Maze Therapeutics, Inc.’s Quiet Period Will End Tomorrow (NASDAQ:MAZE)

Maze Therapeutics’ (NASDAQ:MAZE) quiet period will expire on Wednesday, March 12th. Maze Therapeutics had issued 8,750,000 shares in its initial public offering on January 31st. The total size of the offering was $140,000,000 based on an initial share price of $16.00. During Maze Therapeutics’ quiet period, underwriters and any insiders that worked on the IPO are prevented from issuing any research reports or earnings estimates for the company because of SEC regulations. Following the expiration of the company’s quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on MAZE shares. TD Cowen raised shares of Maze Therapeutics to a “strong-buy” rating in a report on Tuesday, February 25th. Leerink Partnrs raised shares of Maze Therapeutics to a “strong-buy” rating in a research report on Tuesday, February 25th. Guggenheim started coverage on shares of Maze Therapeutics in a research report on Tuesday, February 25th. They set a “buy” rating and a $19.00 price target on the stock. Leerink Partners started coverage on shares of Maze Therapeutics in a report on Tuesday, February 25th. They issued an “outperform” rating and a $28.00 target price on the stock. Finally, JPMorgan Chase & Co. initiated coverage on shares of Maze Therapeutics in a report on Tuesday, February 25th. They issued an “overweight” rating and a $30.00 target price on the stock. Three equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $25.67.

Maze Therapeutics Trading Down 1.8 %

Shares of Maze Therapeutics stock opened at $11.78 on Tuesday. Maze Therapeutics has a 52 week low of $10.08 and a 52 week high of $17.00.

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.